Elebsiran

Phase 3RNA therapy

VVir Biotechnology, Inc.

Elebsiran is one of 3 small molecule programs targeting Viral Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Viral HepatitisActive, not recruiting

Viral HepatitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Viral Hepatitis

#DrugCompanyPhaseTrials

HEPCLUDEX

Gilead

Phase 3

1 2

Elebsiran

VVir Biotechnology, Inc.

Phase 3

1 3

Tobevibart

VVir Biotechnology, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 2Active, not recruiting

HDV Infection

NCT07142811

Q2 2031

Phase 3Active, not recruiting

HDV Infection

NCT06903338

Q3 2031

Phase 3Active, not recruiting

Viral Hepatitis

NCT07128550

Clinical

Trials by Indication[1]

HDV Infection2 trials

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

Active, not recruiting·VVir Biotechnology, Inc.·Phase 3·NCT06903338·124 enrolled

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

Active, not recruiting·VVir Biotechnology, Inc.·Phase 2·NCT07142811·100 enrolled

Viral Hepatitis1 trial

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)

Active, not recruiting·VVir Biotechnology, Inc.·Phase 3·NCT07128550·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Elebsiran. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Elebsiran compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Elebsiran. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vir Biotechnology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 3[1]
Company: VVir Biotechnology, Inc.

Elebsiran

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q2 2031

Q3 2031

Trials by Indication[1]

HDV Infection2 trials

Viral Hepatitis1 trial

References

Drug Info

Quick Facts

Related News